Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER-2 Positive Malignant Carcinoma of Breast”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07179939
What this trial is testing

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

Who this might be right for
HER2-positive Breast Cancer
Fudan University 288
Testing effectiveness (Phase 2)UnknownNCT05346107
What this trial is testing

PLD-cyclophosphamide-Nab-P Continuously Combined With Dual HER2 Blockage for HER2-positive Breast Cancer

Who this might be right for
Breast CancerHER2-positive Breast Cancer
Xijing Hospital 100
Testing effectiveness (Phase 2)Study completedNCT00093145
What this trial is testing

Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer

Who this might be right for
Breast Cancer
Celgene 32
Early research (Phase 1)Study completedNCT05904730
What this trial is testing

Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations

Who this might be right for
Breast CancerOvarian CancerBreast Neoplasms+5 more
Lynkcell Europe 10
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07129187
What this trial is testing

SHR-A1811 for HER2-positive Breast Cancer With Suboptimal Neoadjuvant Response

Who this might be right for
Early Breast CancerHER2 + Breast CancerStage II Breast Cancer+1 more
Chuan Wang 30
Post-approval studies (Phase 4)Looking for participantsNCT07600164
What this trial is testing

Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer

Who this might be right for
HER2 + Breast CancerAdvanced Breast Cancer
Peking University People's Hospital 500
Very early researchStudy completedNCT00949247
What this trial is testing

Docetaxel,Carboplatin,Trastuzumab and Bevacizumab for Breast Cancer and Bone Marrow Micrometastases

Who this might be right for
Breast Cancer
Case Comprehensive Cancer Center 20
Testing effectiveness (Phase 2)Study completedNCT03054363
What this trial is testing

Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer

Who this might be right for
Breast Cancer
University of Colorado, Denver 42
Large-scale testing (Phase 3)Looking for participantsNCT07441460
What this trial is testing

A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer

Who this might be right for
Resectable HER2-positive Breast Cancer
Shanghai JMT-Bio Inc. 1,800
Not applicableNot Yet RecruitingNCT06718335
What this trial is testing

Pyrotinib in HER2-positive Early Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Nie Jianyun 156
Early research (Phase 1)WithdrawnNCT04498520
What this trial is testing

Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8+32 more
Pamela Munster
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07766772
What this trial is testing

Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast Cancer

Who this might be right for
HER2 + Breast CancerAdvanced Breast Cancer
Fujian Cancer Hospital 50
Not applicableStudy completedNCT05253911
What this trial is testing

Tucatinib in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer Who Received at Least Two Prior Anti-HER2 Treatment Regimens.

Who this might be right for
HER2-positive Breast Cancer
iOMEDICO AG 49
Early research (Phase 1)Temporarily pausedNCT05378464
What this trial is testing

Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute 28
Testing effectiveness (Phase 2)Looking for participantsNCT05834764
What this trial is testing

Pyrotinib in Women With High-risk in Early Stage Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 188
Testing effectiveness (Phase 2)Ended earlyNCT00427427
What this trial is testing

Delayed Adjuvant Herceptin® Treatment in Patients With HER-2 Positive Breast Cancer

Who this might be right for
Breast Cancer
Jonsson Comprehensive Cancer Center 75
Not applicableStudy completedNCT04517305
What this trial is testing

Pyrotinib Plus Vinorelbine in HER2+ Metastatic Breast Cancer Patients

Who this might be right for
Breast Cancer
Fudan University 97
Testing effectiveness (Phase 2)Ended earlyNCT03765983
What this trial is testing

GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases

Who this might be right for
Breast Cancer
Dana-Farber Cancer Institute 17
Testing effectiveness (Phase 2)Study completedNCT00545688
What this trial is testing

Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.

Who this might be right for
Breast Cancer
Hoffmann-La Roche 417
Not applicableStudy completedNCT02898727
What this trial is testing

Local Therapy for the Treatment of Brain Metastases From HER2 Positive Breast Cancer

Who this might be right for
Breast Neoplasms
Trans Tasman Radiation Oncology Group 25
Next Page